John Bishop
Vermogen: 2 M $ op 31-05-2026
Vermogen: 2 M $ op 31-05-2026
John E.
Bishop is currently Chief Technical & Quality Officer at Ardelyx, Inc. since 2026.
Formerly, Dr. Bishop was Chief Technology Officer at Lyra Therapeutics, Inc. from 2023 to 2024 and at Forma Therapeutics Holdings, Inc. from 2021 to 2023.
Served as Senior Vice President-Pharmaceutical Sciences at Epizyme, Inc. from 2017 to 2021 and as Senior Vice President-Pharmaceutical Sciences at Genocea Biosciences, Inc. from 2016 to 2017.
Held the position of Senior Vice President-Pharmaceutical Services at Momenta Pharmaceuticals, Inc. from 2006 to 2016.
Worked as Director & Head-Process Development at Millennium Pharmaceuticals, Inc. from 2000 to 2004 and as Leader-Process Research & Development at DuPont Merck Pharmaceutical Co. from 1994 to 2000.
Education includes undergraduate studies at Tufts University, an MBA from Northeastern University, and a doctorate from the University of California, Berkeley.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ARDELYX, INC. 0,14% | 21-05-2026 | 336.845 ( 0,14% ) | 2 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ARDELYX, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| LYRA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 20-06-2024 |
| FORMA THERAPEUTICS HOLDINGS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-02-2023 |
| EPIZYME, INC. | Corporate Officer/Principal | 01-05-2021 |
| GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | 01-05-2017 |
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-05-2016 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 11 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that discovers and develops novel biologic therapies for the treatment of rare immune-mediated diseases | Health Technology |
Genocea Biosciences, Inc.
Genocea Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that discovers and develops novel cancer immunotherapies | Health Technology |
Forma Therapeutics Holdings, Inc.
Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes novel therapeutics to transform the patient living | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Makes pharmaceuticals and drugs | Health Technology |
Tufts University
Tufts University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Develops therapeutics for the treatment of patients with genetically defined cancers | Health Technology |
Ardelyx, Inc.
Ardelyx, Inc. Pharmaceuticals: MajorHealth Technology Discovers and Develops therapeutic therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases | Health Technology |
Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage therapeutics company which develops and commercializes novel integrated drugs for treatment of patients with ear, nose and throat and ENT diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau